RBC Capital analyst Shagun Singh lowered the firm’s price target on Zimmer Biomet (ZBH) to $125 from $130 but keeps an Outperform rating on the shares. The company delivered Q4 results that modestly beat consensus on sales and EPS, while its ex-FX sales growth and EPS outlook for FY25 was at their mid-points, the analyst tells investors in a research note. RBC adds however that both forecasts seem conservative, with room for upside into the second half of FY25 aided primarily by the ramp of new and recently launched products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $130 from $138 at Baird
- Zimmer Biomet Reports Strong 2024 Financial Performance
- ZBH Upcoming Earnings Report: What to Expect?
- Starbucks reports Q1 beat, Frontier proposes Spirit combination: Morning Buzz
- BofA moves to No Rating on Paragon 28 after Zimmer Biomet deal
Questions or Comments about the article? Write to editor@tipranks.com